FDA Investigating 5 Deaths Linked to Monster Energy Drink

FDA Investigating 5 Deaths Linked to Monster Energy Drink

The FDA has received reports of five people who died after consuming Monster Energy — Monster Energy Deathsa high-caffeine energy drink — in the past 3 years, the New York Times reports.

Other adverse events reported to the agency include one nonfatal MI, abdominal pain, vomiting, tremors, and abnormal heart rate. It is unclear whether patients who experienced adverse events also took alcohol or drugs.

In a statement, an FDA spokesperson said that it is the manufacturer’s responsibility to investigate adverse events associated with the beverage, according to the Times. She added that the FDA had not yet established a causal link between the energy drink and the deaths.

A 24-oz. can of Monster Energy contains 240 mg of caffeine, roughly equivalent to two cups of brewed coffee.


New York Times story (Free)

Background: Physician’s First Watch coverage of AAP statement on sports and energy drinks (Free)

Published in Physician’s First Watch October 24, 2012

American Society for Dermatologic Surgery Post-Show Recap

American Society for Dermatologic Surgery Post-Show Recap
Oct 17, 2012

ASDS Post-Show Recap

Laser-buying tips: Less is more for most dermatologic problems

Dermatologic surgeons wanting to set up a laser practice have an array of platforms from which to choose. For maximum return with minimal equipment, a nonablative fractional laser for resurfacing procedures and a modern laser can treat a variety of vascular problems, according to Anne Chapas, M.D.
Dermatologists best for skin procedures

Most primary care physicians believe dermatologists are most qualified to perform skin cancer surgery and cosmetic procedures, according to a recent survey.
Sclerotherapy success starts with knowledge of anatomy

Understand the underlying anatomy, pick the appropriate concentration and type of sclerosing solution, and provide proper post-treatment care for success in sclerotherapy for leg veins, said Mitchel P. Goldman, M.D., at the 2012 annual meeting of the American Society for Dermatologic Surgery.
Nontraditional approach to filler facial augmentation yields enhanced results

Adding volume with injectable fillers is an effective method for restoring a more youthful appearance to an aging face. For optimal results, however, the treatments should not focus only on the middle of the face, according to Michael Kaminer, M.D.
Beware the changing playing field for physician-branded skincare product lines

Before pursuing the creation of a physician-branded skincare line, dermatologists should undertake a comprehensive analysis of the market and the development costs, said Frederic S. Brandt, M.D., at the 2012 annual meeting of the American Society for Dermatologic Surgery.
Gender-specific differences matter when marketing aesthetic services to men

Botulinum toxin treatments in men is a rapidly expanding market, but success in serving this growing population requires physicians to hone gender-specific approaches, according to Michael Eidelman, M.D.
Improve efficiency, patient care services with today’s hottest technology

Advances in technology provide new opportunities for improving office efficiency and better patient care. But they also pose challenges to physicians seeking to take full advantage of these tools, said Amy Derick, M.D. at the 2012 annual meeting of the American Society for Dermatologic Surgery.
Building the framework for a successful cosmetic dermatology practice

High consumer interest in cosmeceuticals and cosmetic procedures may seem to translate into excellent opportunities for revenue and practice growth, but establishing a successful cosmetic dermatology practice is not something that happens overnight, according to Michael Gold, M.D.



If you didn’t get the chance to attend all of the sessions at this year’s Fall Clinical Dermatology Conference, which took place last week in Las Vegas, see what you missed here. Recaps of the meeting’s hottest clinical sessions are below!

Changing cancer guidelines, impending audits impact dermatologic coding

Coding-related changes exerting the most impact on dermatologists involve National Comprehensive Cancer Network (NCCN) guideline changes and increasing numbers of Medicare contractor audits, according to Brett Coldiron, M.D. » Full article


Dermatology Times’ Laser and Light 2012 special supplement is available!

Read about today’s hottest laser and light technologies by visiting: dermatologytimes.com/laserandlight2012

New study shows success in treating acne with photodynamic therapy

The most exciting news regarding photodynamic therapy (PDT) involves a new study showing significant results in treating acne, says the study’s primary investigator. » Full article

Novel antiviral research targets herpes simplex, herpes zoster

Promising developments in antiviral therapies include potential vaccines and treatments for herpes simplex and herpes zoster, said Stephen K. Tyring, M.D., Ph.D., at the 2012 Fall Clinical Dermatology Conference. » Full article

Recent innovations in dermatology address skin cancers, psoriasis and more

New treatments that are currently impacting the field of dermatology address diseases ranging from skin cancers to cold sores, said Mark Lebwohl, M.D., at the 2012 Fall Clinical Dermatology Conference. » Full article

Anatomic understanding fuels advances for filler techniques

A growing knowledge of facial anatomy is driving ongoing refinements in filler strategies and techniques, says Allan S. Wirtzer, M.D., a Sherman Oaks, Calif., dermatologist in private practice. » Full article

Polidocanol boosts leg vein treatment efficacy

Most leg vein treatments are less complex than dermatologists may think, and polidocanol makes such treatments more efficient than ever, an expert says. » Full article

Guidelines cite judicious use of antibiotic prophylaxis for derm surgery

When considering prophylactic antibiotics in dermatologic surgery, knowing what to do can be as important as knowing what not to do. » Full article

Effective surgical closures require planning, follow-up

Achieving optimal surgical closures begins long before — and ends well after — the procedure, says Roger I. Ceilley, M.D., an Iowa dermatologist in private practice and clinical professor of dermatology at the University of Iowa, Iowa City. » Full article

Subscribe Now!

You must click here to continue receiving the Dermatology Times eNews


 Fall Clinical Dermatology Conference website

 Dermatology Times website

 Cosmetic Surgery Times website


Information Technology

Practice Management

Resource Centers

Send comments or questions to Dermatology Times Editor in Chief Amy Stankiewicz atastankiewicz@advanstar.com.

Dermatology Times

Facebook Like us on facebook Twitter Follow us on Twitter

The content of this newsletter is in no way affiliated with Fall Clinical Dermatology Conference…it is produced and brought to you by Dermatology Timesmagazine.

Conference Brief

Conference Brief

Hear one clinical investigator’s data on a topical OAB medication

Hear one clinical investigator’s data on a topical OAB medication that resulted in a significant reduction in urinary incontinence episodes associated with OAB – with a low rate of the side effects that can cause patients to discontinue oral treatments.1-3
In this Urology Times® on-demand podcast, Evan Goldfischer, MD, describes the findings of a phase III, double-blind, randomized, controlled trial of Gelnique 3%TM (oxybutynin) gel 3%, featuring a novel carrier molecule which delivers its active ingredient directly into the bloodstream.1

PODCAST: Dr. Goldfischer on OAB

PODCAST: Dr. Goldfischer on OAB


Gelnique 3% is indicated for the treatment of overactive bladder with
symptoms of urge urinary incontinence, urgency, and frequency.

Important Safety Infomation
The most commonly reported adverse events associated with the use of Gelnique 3% included dry mouth (12.1%), application site erythema (3.7%), and application site rash (3.3%). Gelnique 3% is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma, and in patients who are at risk for these conditions.Gelnique 3% should be used with caution in patients with clinically significant bladder outflow obstruction, myasthenia gravis, gastrointestinal obstructive disorders, ulcerative colitis, intestinal atony, gastroesophageal reflux and those concurrently taking drugs that can cause or exacerbate esophagitis. Angioedema requiring hospitalization and emergency medical treatment has occurred with the first or subsequent doses of oxybutynin pills. If angioedema occurs, Gelnique 3% should be discontinued and appropriate therapy promptly provided. Transference of oxybutynin to another person can occur when vigorous skin-to-skin contact is made with the application site. Patients should be instructed to avoid open flame or smoking until the gel has dried.
Please click here to see full Prescribing Information.
References: 1.Gelnique 3% (oxybutynin) Gelnique 3% [prescribing information]. Parsippany, NJ: Watson Pharma, Inc.; 2011. 2. Data on file. Watson Laboratories, Inc. 3. Basra RK, Wagg A, Chapple C, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102(7):774-779.

Gelnique 3%

BPA in food packaging contributes to childhood obesity

New research has linked bisphenol A (BPA), a chemical commonly found in the lining of metal cans, food
packaging, polycarbonate drink bottles, and other consumer products, to
obesity in children and adolescents.

Investigators analyzed a
subsample of 2,838 children aged 6 through 19 years in the 2003-2008
National Health and Nutrition Examination Surveys for urinary BPA
concentrations and body mass, adjusting for sex, age, race, ethnicity,
caloric intake, serum cotinine and urinary creatinine levels,
television viewing, income-to-poverty ratio, and parental education.

Thirty-four percent of the children were overweight, and 18% were obese. Median urinary BPA concentration was 2.8 ng/mL.

showed that study participants who had high levels of urinary BPA were
at 2.6 times higher risk for obesity than children and adolescents who
had low levels of urinary BPA. For children with the highest levels of
urinary BPA, 22% were obese compared with 10% of those with the lowest
levels of urinary BPA. The association between urinary BPA and obesity
was more prevalent in white children and adolescents than in black or
Hispanic participants.

Obesity was not linked with environmental
exposure to other phenols found in many consumer products including
soaps and sunscreens.

Bisphenol A exposure has been linked to
breast and prostate cancers, infertility, neurologic conditions, and
cardiovascular disease. A recent study of mothers and children concluded that gestational BPA exposure affected behavioral and emotional regulation in girls.

US Food and Drug Administration has banned the use of BPA in baby
bottles and children’s sippy cups but stopped short of banning the
chemical in aluminum and metal cans and in food packaging.

Go back to the current issue of the eConsult.